• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A review of 25 years of National Institute of Health and Care Excellence decision making.

作者信息

Zhang Xin, Tikhonovsky Natalie, Ramagopalan Sreeram V

机构信息

Lane Clark & Peacock LLP, London, W1U 1DQ, UK.

Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK.

出版信息

J Comp Eff Res. 2024 Sep;13(9):e240063. doi: 10.57264/cer-2024-0063. Epub 2024 Jul 16.

DOI:10.57264/cer-2024-0063
PMID:39012494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11363202/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e75/11363202/aafd4c3a943e/cer-13-240063-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e75/11363202/aafd4c3a943e/cer-13-240063-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e75/11363202/aafd4c3a943e/cer-13-240063-g1.jpg

相似文献

1
A review of 25 years of National Institute of Health and Care Excellence decision making.对英国国家卫生与临床优化研究所25年决策历程的回顾。
J Comp Eff Res. 2024 Sep;13(9):e240063. doi: 10.57264/cer-2024-0063. Epub 2024 Jul 16.
2
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.真实世界证据框架的迷宫：从沙漠到丛林！监管机构和卫生技术评估机构的环境扫描和比较。
J Comp Eff Res. 2024 Sep;13(9):e240061. doi: 10.57264/cer-2024-0061. Epub 2024 Aug 12.
3
HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.在美国进行 HTA：美国的 ICER 与英国英格兰和威尔士的 NICE 比较。
J Manag Care Spec Pharm. 2020 Sep;26(9):1162-1170. doi: 10.18553/jmcp.2020.26.9.1162.
4
Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence.比较疗效研究：英国国家卫生与临床优化研究所的经验。
J Clin Oncol. 2012 Dec 1;30(34):4267-74. doi: 10.1200/JCO.2012.42.1974. Epub 2012 Oct 15.
5
Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.卫生技术评估——德国联邦联合委员会/德国卫生保健质量与效率研究所和英国国家卫生与保健优化研究所的决策制定：预算影响的作用。
Value Health. 2023 Jul;26(7):1032-1044. doi: 10.1016/j.jval.2023.02.018. Epub 2023 Mar 13.
6
Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.2015 年至 2021 年，NICE 和 HAS 对肿瘤新药治疗实体瘤的报销建议进行比较评估。
Med Decis Making. 2023 Oct-Nov;43(7-8):961-972. doi: 10.1177/0272989X231188073. Epub 2023 Jul 22.
7
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.药品的健康效益评估：德国、英格兰、苏格兰和澳大利亚决策的国际比较。
Health Policy. 2016 Oct;120(10):1115-1122. doi: 10.1016/j.healthpol.2016.08.001. Epub 2016 Aug 9.
8
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.抗癌药物提交给英国国家卫生与临床优化研究所的不成熟生存数据的流行情况及其对决策的影响。
Value Health. 2021 Apr;24(4):505-512. doi: 10.1016/j.jval.2020.10.016. Epub 2020 Dec 8.
9
The (possible) impact of comparative effectiveness research on pharmaceutical industry decision making.比较疗效研究对制药行业决策的（可能）影响。
Clin Pharmacol Ther. 2010 Mar;87(3):264-6. doi: 10.1038/clpt.2009.243.
10
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法，为 NICE 评估提供信息：系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.

本文引用的文献

1
Turning CMS into a Health Technology Assessment Organization.将医疗保险和医疗补助服务中心转变为一个卫生技术评估组织。
N Engl J Med. 2023 Aug 24;389(8):682-684. doi: 10.1056/NEJMp2305280. Epub 2023 Aug 19.
2
Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.癌症药物的卫生技术评估在 G7 国家和大洋洲：一项国际、横断面研究。
Lancet Oncol. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4.
3
The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
基于适应症定价在未来定价和报销政策中的作用：一项系统综述
Value Health. 2022 Apr;25(4):666-675. doi: 10.1016/j.jval.2021.11.1376. Epub 2022 Feb 25.
4
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.肿瘤学中联合治疗方案的估值与支付挑战：多利益相关方国际研讨会观点汇报
BMC Health Serv Res. 2021 May 3;21(1):412. doi: 10.1186/s12913-021-06425-0.